Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4167779 | 0.88 | RIPK1 (0.45) | HTTNPSR1SMN1; SMN2MAPTLMNA | |
| SCHEMBL4167781 | 0.88 | RIPK1 (0.45) | HTTNPSR1SMN1; SMN2MAPTLMNA | |
| SCHEMBL13699638 | 0.87 | SMN1; SMN2 (0.49) | HTTNPSR1SMN1; SMN2MAPTLMNA | |
| SCHEMBL13699556 | 0.86 | AKR1C3 (0.51) | HTTNPSR1SMN1; SMN2MAPTLMNA | |
| SCHEMBL13699554 | 0.85 | AKR1C3 (0.49) | HTTNPSR1SMN1; SMN2MAPTLMNA | |
| SCHEMBL4154819 | 0.83 | CNR1 (0.48) | HTTNPSR1SMN1; SMN2LMNACNR1 | |
| SCHEMBL4160818 | 0.82 | RIPK1 (0.44) | MEN1KMT2A | |
| SCHEMBL4160826 | 0.82 | RIPK1 (0.44) | MEN1KMT2A | |
| SCHEMBL4177222 | 0.82 | CNR1 (0.47) | HTTNPSR1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL13699575 | 0.82 | RIPK1 (0.41) | HTTNPSR1MAPTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | VERNALIS (R&D) (GB) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | CNR2, CNR1, ALK | HTT 2006/4885NPSR1 36/4885SMN1; SMN2 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.